Trial Profile

A phase 2 study of efficacy and safety of NS-089/NCNP-02 in Duchenne muscular dystrophy patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 09 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brogidirsen (Primary)
Indications Duchenne muscular dystrophy
Focus Therapeutic Use
Sponsors Nippon Shinyaku

Most Recent Events

07 Aug 2023 According to NS Pharma media release, additional details will be provided once the trial is ready to begin enrolling participants.
11 Jul 2023 New trial record
07 Jul 2023 According to NS Pharma media release, clinical development of NS-089/NCNP-02 includes this planned Phase 2 study conducted in Japan by Nippon Shinyaku, Additional details will be provided once the trials are ready to begin enrolling participants

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com